tiprankstipranks
Trending News
More News >

Shanghai Fosun Pharmaceutical Strengthens Governance with New Audit Committee

Story Highlights
Shanghai Fosun Pharmaceutical Strengthens Governance with New Audit Committee

Don’t Miss TipRanks’ Half-Year Sale

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.

Shanghai Fosun Pharmaceutical has established an Audit Committee under its board of directors to enhance corporate governance and ensure effective supervision over management. This move aims to improve decision-making efficiency and maintain a robust understanding of the company’s financial and business management. The committee will consist of three to five directors, primarily independent non-executive members, and will oversee both internal and external audits, reinforcing the company’s commitment to transparency and accountability.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating within the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, medical devices, and healthcare services, with a significant presence in both domestic and international markets.

Average Trading Volume: 7,025,116

Technical Sentiment Signal: Buy

Current Market Cap: HK$65.06B

See more data about 2196 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1